Dupont Vincent, Kanagaratnam Lukshe, Goury Antoine, Poitevin Gaël, Bard Mathieu, Julien Gauthier, Bonnivard Michel, Champenois Vanessa, Noel Violaine, Mourvillier Bruno, Nguyen Philippe
Medical Intensive Care Unit, University Hospital of Reims, Reims, France.
EA-3801, SFT CAP-Santé, University of Reims Champagne Ardenne, France.
Clin Infect Dis. 2021 May 18;72(10):1834-1837. doi: 10.1093/cid/ciaa1007.
Excess soluble fms-like tyrosine kinase 1 (sFlt-1), a soluble inhibitor of vascular endothelial growth factor pathway, has been demonstrated to promote endothelial dysfunction. Here, we demonstrate that sFlt-1 plasma levels correlate with respiratory symptom severity, expression of endothelial dysfunction biomarker, and incidence of organ failure in coronavirus disease 2019 patients. Clinical Trials Registration: NCT04394195.
可溶性fms样酪氨酸激酶1（sFlt-1）过量，一种血管内皮生长因子途径的可溶性抑制剂，已被证明可促进内皮功能障碍。在此，我们证明sFlt-1血浆水平与2019冠状病毒病患者的呼吸道症状严重程度、内皮功能障碍生物标志物的表达以及器官衰竭的发生率相关。临床试验注册：NCT04394195。
